Status:

COMPLETED

Obesity, Weight Loss, and Cardiovascular Disease Risk

Lead Sponsor:

Stanford University

Conditions:

Obesity

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The goal of the study is to define the roles played by resistance to insulin-mediated glucose disposal (insulin resistance) and circulating plasma insulin concentrations in: 1) ability to lose weight;...

Detailed Description

While obesity, insulin resistance, and diabetes are highly associated, it is not clear whether insulin resistance and compensatory hyperinsulinemia play important roles in the tendency to gain weight ...

Eligibility Criteria

Inclusion

  • BMI 30-35
  • age 35-65
  • nondiabetic by fasting plasma glucose concentration
  • no active major organ diseases
  • insulin resistant or insulin sensitive

Exclusion

  • anemia
  • pregnant
  • major organ disease
  • active malignancy
  • eating disorder
  • active psychiatric illness
  • chronic inflammatory conditions

Key Trial Info

Start Date :

October 1 2000

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2017

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT00186459

Start Date

October 1 2000

End Date

August 31 2017

Last Update

December 4 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Stanford University School of Medicine

Stanford, California, United States, 94305